MedTrace Logo

Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults

NCT02718469 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2017-04-04

No results posted yet for this study

Summary

The purpose of this study is to assess the safety profile of the Zaire Ebola vaccine and the strength of the immune response.

Conditions

  • Ebola Virus Disease

Interventions

BIOLOGICAL

Ebola Vaccine - low dose

2 x 0.5ml vaccine will be given as intramuscular injections on each of day 1 and day 28

BIOLOGICAL

Ebola Vaccine - mid dose

2 x 0.5ml vaccine will be given as intramuscular injections on each of day 1 and day 28

BIOLOGICAL

Ebola Vaccine - high dose

2 x 1.0ml vaccine will be given as intramuscular injections on each of day 1 and day 28

BIOLOGICAL

Placebo

2 x 0.5ml or 2 x 1.0ml placebo will be given as intramuscular injections on each of day 1 and day 28 depending on cohort

Sponsors & Collaborators

  • Accelovance

    collaborator INDUSTRY

  • United States Department of Defense

    collaborator FED

  • Auro Vaccines LLC

    lead INDUSTRY

Principal Investigators

  • Murray A Kimmel, DO · Optimal Research, LLC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-12-22
Primary Completion
2016-09-15
Completion
2016-09-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02718469 on ClinicalTrials.gov